Search

Your search keyword '"Zorzet, Sonia"' showing total 8 results
Start Over Author "Zorzet, Sonia" Journal investigational new drugs
8 results on '"Zorzet, Sonia"'

1. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study

Author

Coradini, Danila, Pellizzaro, Cinzia, Abolafio, Gabriella, Bosco, Marco, Scarlata, Ignazio, Cantoni, Silvia, Stucchi, Luca, Zorzet, Sonia, Turrin, Claudia, Sava, Gianni, Perbellini, Alberto, and Daidone, Maria Grazia

Subjects
Lung cancer -- Drug therapy, Lung cancer -- Research, Antimitotic agents -- Dosage and administration, Antineoplastic agents -- Dosage and administration, Hyaluronic acid -- Dosage and administration, Pharmaceuticals and cosmetics industries
Abstract

Byline: Danila Coradini (1), Cinzia Pellizzaro (1), Gabriella Abolafio (1), Marco Bosco (2), Ignazio Scarlata (3), Silvia Cantoni (3), Luca Stucchi (2), Sonia Zorzet (4), Claudia Turrin (4,5), Gianni Sava (4,5), Alberto Perbellini (6), Maria Grazia Daidone (1) Keywords: hyaluronic acid; butyric ester; cell lung carcinoma Abstract: New promising compounds, derived from the esterification of hyaluronic acid with butyric acid, were investigated in vitro on a non-small cell lung carcinoma cell line (NCI-H460) and an its metastatic subclone (NCI-H460M). All new compounds exerted a dose-dependent inhibitory effect on both cell lines, which expressed CD44, the specific surface receptor for hyaluronic acid, in a very high percentage of cells (90%). HE1, the most effective of these compounds, was 10-fold more effective than sodium butyrate (NaB) in inhibiting cell proliferation. Similarly to NaB, after 24 hours of treatment, HE1 affected the expression of three cell cycle-related proteins (p27.sup.kip1, p53 and p21.sup.waf1) responsible for growth arrest, indicating that the presence of the hyaluronic acid backbone does not interfere with the biologic activity. Intratumoral treatment with HE1 demonstrated a marked efficacy on primary tumor growth and on lung metastases formation of the murine Lewis Lung Carcinoma model. Altogether, present findings suggest a possible clinical application of these novel butyric pro-drugs in primary and metastatic lung cancer. Author Affiliation: (1) Unit of Biomolecular Determinants in Prognosis and Therapy, Experimental Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano (2) POLYtech, Area di Ricerca, Padriciano 99, Trieste (3) BBCM Department, University of Trieste, Italy (4) Department of Biomedical Science, University of Trieste, Italy (5) Callerio Foundation, Via Fleming 22, Trieste (6) Coimex S.c.r.l., Via P. Borsellino 2, Reggio Emilia, Italy Article History: Registration Date: 21/10/2004

Published
2004

2. Primary Tumor, Lung and Kidney Retention and Antimetastasis Effect of NAMI-A Following Different Routes of Administration

Author

Cocchietto, Moreno, Zorzet, Sonia, Sorc, Alenka, and Sava, Gianni

Subjects
Imidazole -- Research, Cancer -- Drug therapy, Pharmaceuticals and cosmetics industries
Abstract

Byline: Moreno Cocchietto (1), Sonia Zorzet (2), Alenka Sorc (1), Gianni Sava (1,2) Keywords: NAMI-A; tumor; metastasis; distribution; experimental Abstract: Imidazolium-trans-dimethylsulfoxideimidazoletetrachlororuthenate (NAMI-A) is a ruthenium compound effective on solid tumor metastases. In this study, we evaluated the effects of different routes of administration of NAMI-A on the distribution to primary tumor, lungs and kidneys in BD2F1 hybrids with Lewis lung carcinoma or in CBA inbred mice with MCa mammary carcinoma. NAMI-A concentration and the percentage of cumulative dose (%D .sub.tot) retained in these tissues is independent of the animal strain and of the tumor model used. Also the presence of the tumor does not change the distribution of NAMI-A in the lungs and in the kidneys. A dose-dependent antimetastatic effect is evident with intraperitoneal (i.p.) treatments at three different doses. Treatment of tumor bearing mice with NAMI-A administered i.p., per os or by aerosol showed a similar effect on lung metastases, although the concentration of ruthenium reached in the lungs was markedly different. On the basis of the data obtained, we can conclude that the antimetastatic effects are related to the amount of NAMI-A administered, rather than to the lung's concentration of the compound. Author Affiliation: (1) Callerio Foundation-Onlus, Institutes of Biological Research, Trieste, Italy (2) Department of Biomedical Sciences, University of Trieste, Italy Article History: Registration Date: 05/10/2004

Published
2003

7. Primary Tumor, Lung and Kidney Retention and Antimetastasis Effect of NAMI-A Following Different Routes of Administration

Author

Alenka Sorc, Sonia Zorzet, Moreno Cocchietto, Gianni Sava, Cocchietto, M., Zorzet, Sonia, Sorc, A., Sava, Gianni, M., Cocchietto, and A., Sorc

Subjects
Pathology, medicine.medical_specialty, Lung Neoplasms, Administration, Oral, Antineoplastic Agents, Mammary Neoplasms, Animal, Mice, Inbred Strains, Pharmacology, Kidney, Ruthenium, Metastasis, Carcinoma, Lewis Lung, Mice, Route of administration, chemistry.chemical_compound, Species Specificity, Pharmacokinetics, Antimetastatic Agent, Administration, Inhalation, Organometallic Compounds, medicine, Animals, NAMI-A, Dimethyl Sulfoxide, Pharmacology (medical), Neoplasm Metastasis, Lung, Aerosols, business.industry, Lewis lung carcinoma, respiratory system, medicine.disease, Primary tumor, Disease Models, Animal, medicine.anatomical_structure, Liver, Oncology, chemistry, Ruthenium Compounds, Female, business, Injections, Intraperitoneal
Abstract

Imidazolium-trans-dimethylsulfoxideimidazoletetrachlororuthenate (NAMI-A) is a ruthenium compound effective on solid tumor metastases. In this study, we evaluated the effects of different routes of administration of NAMI-A on the distribution to primary tumor, lungs and kidneys in BD2F1 hybrids with Lewis lung carcinoma or in CBA inbred mice with MCa mammary carcinoma. NAMI-A concentration and the percentage of cumulative dose (%Dtot) retained in these tissues is independent of the animal strain and of the tumor model used. Also the presence of the tumor does not change the distribution of NAMI-A in the lungs and in the kidneys. A dose-dependent antimetastatic effect is evident with intraperitoneal (i.p.) treatments at three different doses. Treatment of tumor bearing mice with NAMI-A administered i.p., per os or by aerosol showed a similar effect on lung metastases, although the concentration of ruthenium reached in the lungs was markedly different. On the basis of the data obtained, we can conclude that the antimetastatic effects are related to the amount of NAMI-A administered, rather than to the lung's concentration of the compound.

Published
2003
Full Text
View/download PDF

8. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study

Author

Alberto Perbellini, Gianni Sava, Maria Grazia Daidone, Gabriella Abolafio, Ignazio Scarlata, Silvia Cantoni, C. Pellizzaro, Claudia Turrin, Luca Stucchi, Marco Bosco, Sonia Zorzet, Danila Coradini, Coradini, D., Pellizzaro, C., Abolafio, G., Bosco, M., Scarlata, I., Cantoni, S., Stucchi, L., Zorzet, Sonia, Turrin, C., Sava, Gianni, Perbellini, A., and Daidone, M. G.

Subjects
Experimental tumour, Lung Neoplasms, Cell, Blotting, Western, Antineoplastic Agents, NA-But, Biology, Butyric acid, chemistry.chemical_compound, Carcinoma, Lewis Lung, Mice, HDAC inhibitor, HDAC inhibitors, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Hyaluronic acid, medicine, Animals, Humans, Pharmacology (medical), Hyaluronic Acid, Pharmacology, Dose-Response Relationship, Drug, Experimental tumours, Cell growth, CD44, Lewis lung carcinoma, Sodium butyrate, Esters, Antineoplastic, Flow Cytometry, Butyrates, medicine.anatomical_structure, Oncology, chemistry, Biochemistry, Cell culture, Cancer research, biology.protein, Cell Division
Abstract

New promising compounds, derived from the esterification of hyaluronic acid with butyric acid, were investigated in vitro on a non-small cell lung carcinoma cell line (NCI-H460) and an its metastatic subclone (NCI-H460M). All new compounds exerted a dose-dependent inhibitory effect on both cell lines, which expressed CD44, the specific surface receptor for hyaluronic acid, in a very high percentage of cells (90%). HE1, the most effective of these compounds, was 10-fold more effective than sodium butyrate (NaB) in inhibiting cell proliferation. Similarly to NaB, after 24 hours of treatment, HE1 affected the expression of three cell cycle-related proteins (p27(kip1), p53 and p21(waf1)) responsible for growth arrest, indicating that the presence of the hyaluronic acid backbone does not interfere with the biologic activity. Intratumoral treatment with HE1 demonstrated a marked efficacy on primary tumor growth and on lung metastases formation of the murine Lewis Lung Carcinoma model. Altogether, present findings suggest a possible clinical application of these novel butyric pro-drugs in primary and metastatic lung cancer.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results